IBζ作为炎症性关节炎发病原体的中央调节器
Gaurav Swarnkar1, Musarrat Naaz1, Dorothy Mims1
1Washington University School of Medicine, St. Louis, Missouri.
Arthritis & rheumatology (Hoboken, N.J.)
|September 16, 2024
概括
准IBζ,这是类风湿性关节炎的关键炎症途径,可以减少关节炎症和损伤. 抑制IBζ节省了有益的NF-B功能,为炎症性关节炎提供了更安全的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 类风湿病学 类风湿病学
背景情况:
- 目前的炎症性关节炎疗法具有不同的疗效和副作用.
- 核因子-kappa B (NF-B) 对于炎症性细胞因子的产生至关重要,但对于生理过程至关重要.
- 针对NF-B选择性控制炎症细胞因子的下游途径是有利的.
研究的目的:
- 研究IFBζ的作用,NF-B的炎症特征,在炎症性关节炎症中.
- 评估IBζ作为类风湿性关节炎的潜在治疗标.
主要方法:
- 生成的小鼠具有髓状,淋巴状和Nfkbiz (编码IBζ的基因) 的全球删除.
- 在这些模型中诱导血清转移诱导的关节炎.
- 服用IBζ的药理抑制剂,包括二甲基伊塔科纳酸 (DI) 和8-基因 (HQ).
- 使用各种技术分析突组织,包括免疫组织化学和流细胞计.
主要成果:
- 全球删除Nfkbiz通过减少炎症细胞和增加抗炎/再生细胞,改善了实验性炎症性关节炎.
- 免疫反应基因-1的表达和伊塔康酸盐的产生增加.
- 甲基伊他康酸 (DI) 和8-基 (HQ) 抑制了IBζ介导的炎症因素,并在体内减少关节胀和损伤.
- IB抑制节省了有益的NF-B功能.
结论:
- IBζ是炎症性关节炎的特定治疗点,包括类风湿性关节炎.
- 抑制IBζ提供了一种有前途的策略,通过选择性向病理性炎症,同时保持基本的生理功能.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
T Cell Types and Functions
961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118


